Hologic, Inc. (NASDAQ:HOLX) Receives $84.62 Consensus Target Price from Analysts

Hologic, Inc. (NASDAQ:HOLX) has received an average rating of “Hold” from the seventeen analysts that are covering the company, MarketBeat Ratings reports. Eleven investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $84.62.

HOLX has been the topic of a number of recent research reports. Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Evercore ISI reduced their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Royal Bank of Canada reduced their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Finally, Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th.

Hologic Price Performance

HOLX opened at $60.86 on Tuesday. Hologic has a fifty-two week low of $59.06 and a fifty-two week high of $84.67. The firm has a 50-day moving average of $64.30 and a 200 day moving average of $72.59. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm has a market cap of $13.66 billion, a P/E ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts expect that Hologic will post 4.28 EPS for the current year.

Institutional Trading of Hologic

Institutional investors and hedge funds have recently made changes to their positions in the stock. General Partner Inc. bought a new stake in Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment lifted its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its position in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.